PMID- 37873509
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231026
IS  - 1178-7015 (Print)
IS  - 1178-7015 (Electronic)
IS  - 1178-7015 (Linking)
VI  - 16
DP  - 2023
TI  - Efficacy, safety, and Pharmacoeconomics of Three Common Strategies for Pediatric 
      Alopecia Areata Patients: A Retrospective Cohort Study.
PG  - 2947-2956
LID - 10.2147/CCID.S425534 [doi]
AB  - OBJECTIVE: To evaluate and explore the efficacy, safety, and pharmacoeconomics of 
      three common strategies for pediatric alopecia areata. METHODS: Chinese pediatric 
      alopecia areata patients meeting the criteria were included and divided into 
      three groups based on the received treatments. The efficacy, adverse events and 
      pharmacoeconomics of these treatments were retrospectively analyzed. RESULTS: 
      Twenty-four pediatric AA patients were recruited in this study. 100% (12/12) of 
      patients from the traditional group achieved SALT100. In the tofacitinib group, 
      40.0% (2/5) of patients achieved SALT50. 20.0% (1/5) of patients achieved SALT75 
      and 40.0% (2/5) of patients achieved SALT100. In the MN group, 42.86% (3/7) of 
      patients were non-responders. 14.28 (1/7) of patients achieved SALT75 and 42.86% 
      (3/7) of patients achieved SALT100. The adverse effects (AEs) were mild in all 
      three groups, and none of the patients discontinued the treatments due to the 
      AEs. Comparing the other two groups, the MN treatment would be more 
      time-intensive and more expensive. CONCLUSION: For newly diagnosed or naive 
      pediatric patients, the traditional treatment was the first-line approach. For 
      long-duration, severe and refractory patients, tofacitinib and microneedling can 
      be alternative options.
CI  - (c) 2023 Zhou et al.
FAU - Zhou, Jiong
AU  - Zhou J
AD  - Department of Dermatology, Second Affiliated Hospital, Zhejiang University School 
      of Medicine, Hangzhou, People's Republic of China.
FAU - Yang, Yang
AU  - Yang Y
AD  - Department of Dermatology, Second Affiliated Hospital, Zhejiang University School 
      of Medicine, Hangzhou, People's Republic of China.
FAU - Xu, Mengjun
AU  - Xu M
AD  - Department of Dermatology, Second Affiliated Hospital, Zhejiang University School 
      of Medicine, Hangzhou, People's Republic of China.
FAU - Lyu, Zhongfa
AU  - Lyu Z
AD  - Department of Dermatology, Second Affiliated Hospital, Zhejiang University School 
      of Medicine, Hangzhou, People's Republic of China.
FAU - Wu, Xianjie
AU  - Wu X
AUID- ORCID: 0000-0002-5604-5801
AD  - Department of Dermatology, Second Affiliated Hospital, Zhejiang University School 
      of Medicine, Hangzhou, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20231018
PL  - New Zealand
TA  - Clin Cosmet Investig Dermatol
JT  - Clinical, cosmetic and investigational dermatology
JID - 101543449
PMC - PMC10590599
OTO - NOTNLM
OT  - alopecia areata
OT  - efficacy
OT  - microneedling
OT  - pediatric
OT  - tofacitinib
COIS- The authors report no conflicts of interest in this work.
EDAT- 2023/10/24 06:41
MHDA- 2023/10/24 06:42
PMCR- 2023/10/18
CRDT- 2023/10/24 03:58
PHST- 2023/06/14 00:00 [received]
PHST- 2023/09/14 00:00 [accepted]
PHST- 2023/10/24 06:42 [medline]
PHST- 2023/10/24 06:41 [pubmed]
PHST- 2023/10/24 03:58 [entrez]
PHST- 2023/10/18 00:00 [pmc-release]
AID - 425534 [pii]
AID - 10.2147/CCID.S425534 [doi]
PST - epublish
SO  - Clin Cosmet Investig Dermatol. 2023 Oct 18;16:2947-2956. doi: 
      10.2147/CCID.S425534. eCollection 2023.